title: Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML).
abstract: Bcr-Abl is the predominant therapeutic target in chronic myeloid leukemia (CML), and tyrosine kinase inhibitors (TKIs) that inhibit Bcr-Abl have been successful in treating CML. With progression of CML disease especially in blast crisis stage, cells from CML patients become resistant to imatinib mesylate (IM) and other TKIs, resulting in relapse. Because Bcr-Abl is known to drive multiple signaling pathways, the study of the regulation of stability of Bcr-Abl in IM-resistant CML cells is a critical issue as a possible therapeutic strategy. Here, we report that a new dual-kinase chemical inhibitor, ON044580, induced apoptosis of Bcr-Abl+ IM-sensitive, IM-resistant cells, including the gatekeeper Bcr-Abl mutant, T315I, and also cells from blast crisis patients. In addition, IM-resistant K562-R cells, cells from blast crisis CML patients, and all IM-resistant cell lines tested had reduced ability to form colonies in soft agar in the presence of 0.5 µM ON044580. In in vitro kinase assays, ON044580 inhibited the recombinant Jak2 and Abl kinase activities when the respective Jak2 and Abl peptides were used as substrates. Incubation of the Bcr-Abl+ cells with ON044580 rapidly reduced the levels of the Bcr-Abl protein and also reduced the expression of HSP90 and its client protein levels. Lysates of Bcr-Abl+ cell lines were found to contain a large signaling network complex composed of Bcr-Abl, Jak2, HSP90, and its client proteins as detected by a gel filtration column chromatography, which was rapidly disrupted by ON044580. Therefore, targeting Jak2 and Bcr-Abl kinases is an effective way to destabilize Bcr-Abl and its network complex, which leads to the onset of apoptosis in IM-sensitive and IM-resistant Bcr-Abl+ cells. This inhibitory strategy has potential to manage all types of drug-resistant CML cells, especially at the terminal blast crisis stage of CML, where TKIs are not clinically useful.
authors.affiliation: Department of Molecular Pathology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
authors.forename: Ajoy K
authors.initials: AK
authors.lastname: Samanta
authors.forename: Sandip N
authors.initials: SN
authors.lastname: Chakraborty
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Ellen
authors.initials: E
authors.lastname: Schlette
authors.forename: E Premkumar
authors.initials: EP
authors.lastname: Reddy
authors.forename: Ralph B
authors.initials: RB
authors.lastname: Arlinghaus
references.citation: Biochem J. 2005 Dec 1;392(Pt 2):335-44
references.pmid: 16048438
references.citation: Oncogene. 2009 Apr 9;28(14):1669-81
references.pmid: 19234487
references.citation: Nature. 1973 Jun 1;243(5405):290-3
references.pmid: 4126434
references.citation: Cancer Res. 2004 Jan 15;64(2):672-7
references.pmid: 14744784
references.citation: Nature. 2003 Sep 25;425(6956):407-10
references.pmid: 14508491
references.citation: Blood. 2004 Apr 15;103(8):3167-74
references.pmid: 15070699
references.citation: Biochem Pharmacol. 1998 Sep 15;56(6):675-82
references.pmid: 9751071
references.citation: Cancer Res. 1996 Aug 1;56(15):3426-30
references.pmid: 8758906
references.citation: Leukemia. 2007 Aug;21(8):1658-68
references.pmid: 17541402
references.citation: J Biol Chem. 2004 Feb 27;279(9):7576-83
references.pmid: 14662759
references.citation: Nat Rev Cancer. 2005 Oct;5(10):761-72
references.pmid: 16175177
references.citation: Br J Cancer. 2006 Oct 9;95(7):775-81
references.pmid: 16953242
references.citation: Cancer Res. 2006 Jul 1;66(13):6468-72
references.pmid: 16818614
references.citation: Expert Opin Emerg Drugs. 2002 Oct;7(2):277-88
references.pmid: 15989551
references.citation: Science. 1964 Jun 5;144(3623):1229-31
references.pmid: 14150328
references.citation: Oncogene. 2001 Sep 27;20(43):6188-95
references.pmid: 11593427
references.citation: Drug Resist Updat. 1999 Jun;2(3):165-172
references.pmid: 11504487
references.citation: Nat Rev Cancer. 2007 Jun;7(6):441-53
references.pmid: 17522713
references.citation: Blood. 2003 Jan 15;101(2):690-8
references.pmid: 12509383
references.citation: Blood. 2007 Apr 15;109(8):3207-13
references.pmid: 17185463
references.citation: Cancer Cell. 2002 Aug;2(2):117-25
references.pmid: 12204532
references.citation: Blood. 2007 Apr 15;109(8):3470-8
references.pmid: 17202319
references.citation: J Med Chem. 2005 Apr 7;48(7):2526-33
references.pmid: 15801842
references.citation: Blood. 2007 Jan 15;109(2):497-9
references.pmid: 16990591
references.citation: Blood. 2003 Jul 1;102(1):276-83
references.pmid: 12623848
references.citation: Nat Rev Cancer. 2007 May;7(5):345-56
references.pmid: 17457302
references.citation: Expert Opin Emerg Drugs. 2005 Feb;10(1):137-49
references.pmid: 15757409
references.citation: Blood. 2002 Oct 15;100(8):3041-4
references.pmid: 12351420
references.citation: Cell. 1993 Oct 8;75(1):175-85
references.pmid: 8402896
references.citation: Genes Cancer. 2010 Apr;1(4):331-45
references.pmid: 20717479
references.citation: Biochem Soc Trans. 2007 Nov;35(Pt 5):1347-51
references.pmid: 17956348
references.citation: Lancet Oncol. 2007 Mar;8(3):273-4
references.pmid: 17329198
references.citation: Pharmacol Ther. 1998 Aug;79(2):129-68
references.pmid: 9749880
references.citation: EMBO J. 2002 Nov 1;21(21):5766-74
references.pmid: 12411494
references.citation: Blood. 1999 Jun 15;93(12):4154-66
references.pmid: 10361113
references.citation: Cell Cycle. 2004 Sep;3(9):1098-100
references.pmid: 15326368
references.citation: Oncogene. 2008 Feb 14;27(8):1175-8
references.pmid: 17724475
references.citation: Expert Rev Anticancer Ther. 2007 Nov;7(11):1529-36
references.pmid: 18020922
references.citation: Blood. 2005 Feb 15;105(4):1768-76
references.pmid: 15514006
references.citation: Biopolymers. 2010 Mar;93(3):211-7
references.pmid: 19697319
references.citation: Jpn J Infect Dis. 2009 Sep;62(5):392-3
references.pmid: 19762993
references.citation: Expert Opin Biol Ther. 2002 Jan;2(1):3-24
references.pmid: 11772336
references.citation: Semin Oncol. 2003 Oct;30(5):709-16
references.pmid: 14571418
references.citation: Leukemia. 2008 Jul;22(7):1402-9
references.pmid: 18418407
references.citation: Blood. 2004 Jun 1;103(11):4010-22
references.pmid: 14982876
references.citation: Ann Oncol. 2003 Aug;14(8):1169-76
references.pmid: 12881371
references.citation: Hematology Am Soc Hematol Educ Program. 2005;:188-94
references.pmid: 16304379
references.citation: Cancer Cell. 2005 Nov;8(5):355-68
references.pmid: 16286244
references.citation: Oncogene. 2002 Oct 17;21(47):7137-46
references.pmid: 12370803
references.citation: Trends Mol Med. 2004 Jun;10(6):283-90
references.pmid: 15177193
references.citation: Cell Cycle. 2009 May 1;8(9):1338-43
references.pmid: 19342894
references.citation: Oncogene. 2008 May 8;27(21):3054-9
references.pmid: 18037959
references.citation: ChemMedChem. 2006 Dec;1(12):1331-40
references.pmid: 17066389
references.citation: EMBO J. 1994 Feb 15;13(4):764-73
references.pmid: 8112292
references.citation: Cancer Res. 2003 Nov 15;63(22):7777-84
references.pmid: 14633703
references.citation: Cancer Cell. 2003 Mar;3(3):213-7
references.pmid: 12676580
references.citation: J Clin Oncol. 2006 Nov 20;24(33):e51-2
references.pmid: 17114651
references.citation: Leukemia. 2001 Oct;15(10):1537-43
references.pmid: 11587211
references.citation: Hematology Am Soc Hematol Educ Program. 2007;:384-91
references.pmid: 18024655
references.citation: N Engl J Med. 1999 Apr 29;340(17):1330-40
references.pmid: 10219069
references.citation: Curr Mol Med. 2009 Jun;9(5):654-64
references.pmid: 19601813
references.citation: J Biol Chem. 2000 Oct 20;275(42):32499-507
references.pmid: 10913439
references.citation: Leuk Lymphoma. 2002 May;43(5):961-8
references.pmid: 12148906